AngioSoma Committed to Expanding Cosmeceutical Future
New Industry Data and Product Roadmap Align for Optimistic Outlook
Houston, TX - (NewMediaWire) - November 8, 2018 - AngioSoma (OTC: SOAN), a leading biotechnology research and development company, reaffirms its position and future goals within the cosmeceutical space based on new industry data.
The global cosmeceuticals market was valued at USD 46.93 billion in 2017, and is expected to reach a value of USD 80.36 billion by 2023 at a CAGR of 9.38%, over the forecast period (2018—2023). With an aging population and life expectancy rising, the demand for natural youth-sustaining cosmeceutical products will be spiking for the foreseeable future. Plant stem cell based and antioxidant rich products will usher in a new generation of cosmeceutical products that AngioSoma plans on developing in the near term.
“We are committed to expanding our reach in this industry,” said Alex Blankenship, President of AngioSoma. “As people value natural alternatives more, our products will become a more attractive choice in the future. Given our already successful products and the new cosmeceutical products launching in the near future, AngioSoma is poised to capture market share going forward.”
You can view and purchase products on Amazon.com: Go to Amazon Now
Also, products can be found on our ecommerce site: YouthfulBrilliance.com.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (https://angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Contact AngioSoma, Inc. Alex Blankenship investors@AngioSoma.com
Source: AngioSoma, Inc.